BidaskClub upgraded shares of Cutera, Inc. (NASDAQ:CUTR) from a buy rating to a strong-buy rating in a research note issued to investors on Wednesday.
A number of other equities analysts have also weighed in on CUTR. Sidoti reiterated a buy rating and issued a $32.00 price target (up previously from $30.00) on shares of Cutera in a research report on Friday, July 7th. Zacks Investment Research upgraded Cutera from a hold rating to a buy rating and set a $29.00 price target for the company in a research report on Tuesday, June 27th. Roth Capital assumed coverage on Cutera in a research report on Monday, June 26th. They issued a buy rating and a $32.00 price target for the company. Finally, TheStreet lowered Cutera from a b- rating to a c rating in a research report on Monday, May 1st. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Cutera presently has a consensus rating of Buy and a consensus target price of $31.50.
Shares of Cutera (NASDAQ:CUTR) traded up 0.2204% on Wednesday, reaching $27.0595. 68,097 shares of the company traded hands. The company has a market capitalization of $374.99 million, a PE ratio of 103.6762 and a beta of 0.60. Cutera has a 52-week low of $10.43 and a 52-week high of $29.25. The firm has a 50-day moving average of $23.01 and a 200-day moving average of $20.36.
Cutera (NASDAQ:CUTR) last announced its earnings results on Monday, May 1st. The medical device company reported ($0.07) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.07). Cutera had a return on equity of 9.21% and a net margin of 2.89%. The business had revenue of $29.30 million during the quarter, compared to analysts’ expectations of $29 million. During the same quarter last year, the business posted ($0.16) earnings per share. The company’s quarterly revenue was up 30.8% on a year-over-year basis. On average, equities research analysts forecast that Cutera will post $0.46 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Cutera, Inc. (CUTR) Upgraded at BidaskClub” was first reported by Ticker Report and is the property of of Ticker Report. If you are viewing this report on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The correct version of this report can be accessed at https://www.tickerreport.com/banking-finance/2722940/cutera-inc-cutr-upgraded-at-bidaskclub.html.
In related news, EVP Larry Laber sold 1,000 shares of the stock in a transaction on Wednesday, June 28th. The stock was sold at an average price of $25.88, for a total value of $25,880.00. Following the completion of the transaction, the executive vice president now owns 73,140 shares in the company, valued at approximately $1,892,863.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Ronald J. Santilli sold 60,991 shares of the stock in a transaction on Monday, May 8th. The shares were sold at an average price of $19.99, for a total value of $1,219,210.09. Following the completion of the transaction, the chief financial officer now owns 174,025 shares of the company’s stock, valued at approximately $3,478,759.75. The disclosure for this sale can be found here. Insiders sold a total of 160,410 shares of company stock valued at $3,410,284 in the last quarter. 3.30% of the stock is currently owned by corporate insiders.
A number of large investors have recently made changes to their positions in the company. Renaissance Technologies LLC increased its stake in shares of Cutera by 13.4% in the first quarter. Renaissance Technologies LLC now owns 1,205,400 shares of the medical device company’s stock valued at $24,952,000 after buying an additional 142,140 shares in the last quarter. Dalton Greiner Hartman Maher & Co. increased its stake in shares of Cutera by 2.3% in the first quarter. Dalton Greiner Hartman Maher & Co. now owns 201,064 shares of the medical device company’s stock valued at $4,162,000 after buying an additional 4,615 shares in the last quarter. State Street Corp increased its stake in shares of Cutera by 1.9% in the fourth quarter. State Street Corp now owns 171,125 shares of the medical device company’s stock valued at $2,970,000 after buying an additional 3,191 shares in the last quarter. JPMorgan Chase & Co. increased its stake in shares of Cutera by 60.4% in the first quarter. JPMorgan Chase & Co. now owns 169,401 shares of the medical device company’s stock valued at $3,506,000 after buying an additional 63,758 shares in the last quarter. Finally, Acadian Asset Management LLC increased its stake in shares of Cutera by 57.0% in the first quarter. Acadian Asset Management LLC now owns 145,347 shares of the medical device company’s stock valued at $3,009,000 after buying an additional 52,751 shares in the last quarter. 81.42% of the stock is owned by hedge funds and other institutional investors.
Cutera, Inc is a medical device company. The Company is engaged in the design, development, manufacture, marketing and servicing of laser and other energy-based aesthetics systems for practitioners across the world. The Company offers products based on product platforms, such as enlighten, excel HR, truSculpt, excel V and xeo, each of which enables physicians and other practitioners to perform aesthetic procedures for customers.
Receive News & Ratings for Cutera Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cutera Inc. and related companies with MarketBeat.com's FREE daily email newsletter.